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Introduction {#sec006}
============

Alveolar echinococcosis (AE), one of the most Iethal human helminthic infections, is acquired by ingestion of eggs from *Echinococcus multilocularis*. AE behaves biologically like a malignant tumor with a tendency to metastasize into distant organs \[[@pntd.0003964.ref001]--[@pntd.0003964.ref005]\]. The treatment of choice is radical resection, however, only 30--40% of patients have resectable liver lesions \[[@pntd.0003964.ref001],[@pntd.0003964.ref004],[@pntd.0003964.ref006],[@pntd.0003964.ref007]\]. In the pre-chemotherapy area, the 10-year survival rate of patients with non-resectable AE was less than 10% \[[@pntd.0003964.ref001],[@pntd.0003964.ref008]\]. With the advent of benzimidazole based chemotherapy, the outcome of non-resectable AE has dramatically improved. Long-term chemotherapy with benzimidazoles improves the 10-year survival rate of non-resectable AE to 80% \[[@pntd.0003964.ref001],[@pntd.0003964.ref008]--[@pntd.0003964.ref010]\]. However, whether long-term chemotherapy is parasitocidal (curative) or remains parasitostatic, with the need for life-long therapy is still unclear \[[@pntd.0003964.ref011]--[@pntd.0003964.ref015]\]. The lack of reliable non-invasive methods for assessing parasite viability remains a major problem. Thus, absence of AE-recurrence two to three years after stopping chemotherapy is retrospectively considered as evidence of a curative effect \[[@pntd.0003964.ref011],[@pntd.0003964.ref012],[@pntd.0003964.ref014]\].

Recently, FDG-PET (fluorodeoxy-glucose-positron emission tomography) \[[@pntd.0003964.ref016],[@pntd.0003964.ref017]\] and antibody levels against the recombinant EmII/3-10 antigen \[[@pntd.0003964.ref018]\] have been described as two new promising methods for assessing parasite viability in patients.

Increased FDG-uptake in functional PET-imaging is observed in tumoral, inflammatory and infectious lesions. Decrease in FDG-uptake is considered as a useful metabolic parameter for assessing anti-tumoral/anti-infectious pharmacotherapy \[[@pntd.0003964.ref019]--[@pntd.0003964.ref022]\]. It was hypothesized that an increased FDG-uptake of AE lesions reflects parasite viability \[[@pntd.0003964.ref016],[@pntd.0003964.ref017]\]. The reverse assumption that a decrease in FDG-uptake during chemotherapy may be a reliable parameter of parasite death, however, was not confirmed in a recent study \[[@pntd.0003964.ref014]\].

Serum levels of specific anti-Emll/3-10 antigen appear to be another promising parameter for parasite viability \[[@pntd.0003964.ref018]\]. In a preliminary study, a putative parasitocidal effect was observed in two third of patients with non-resectable AE following abrogation of long-term chemotherapy \[[@pntd.0003964.ref012]\]. A recent follow-up study showed that the anti-Emll/3-10 profile normalized in 8 of 9 patients without AE-recurrence. In contrast, high antibody levels were found in 7 of 9 patients with AE-recurrence \[[@pntd.0003964.ref018]\].

The aim of the present study was to prospectively evaluate whether long-term chemotherapy is parasitocidal in patients with AE, and whether FDG-PET/CT in combination with serum anti-Emll/3-10 levels can be used to select patients in whom chemotherapy can be stopped with a low risk of AE-recurrence. This is clinically highly relevant because the frequency of AE is rising in Europe and Asia \[[@pntd.0003964.ref010],[@pntd.0003964.ref023]--[@pntd.0003964.ref025]\], and the parasite is emerging in parts of North America \[[@pntd.0003964.ref026]\] and furthermore the costs associated with long-term chemotherapy are high (up to 16 300 Euro/patient-year) \[[@pntd.0003964.ref009]\].

Methods {#sec007}
=======

Study design {#sec008}
------------

Prospective treatment abrogation study including patients with non-resectable AE and previous chemotherapy with either albendazole or mebendazole for at least two years. The benzimidazole dose was adjusted to reach appropriate serum level 4 hours after the morning dose (albendazole: \>1umol/l, mebendazole:\>250 nmol/l) \[[@pntd.0003964.ref007]\].

Inclusion criteria: Non-resectable AE, benzimidazole treatment for at least two years, absence of FDG uptake (negative FDG-PET/CT scan) and negative anti-EmII/3-10 levels.

Exclusion criteria: Positive FDG-PET/CT scan and/or detectable anti-EmII/3-10 levels, non-Compliance of the patient, reduced life expectation (age \>80 years, concomitant malignoma, preterminal disease e.g. renal, hepatic, or pulmonal) and pregnancy.

Patients were selected among a group 34 patients with non resectable AE lesions. Subgroup A included 11 patients with newly diagnosed AE who had been closely followed by FDG-PET/CT (at 6, 12 and 24 months) and EmII/3-10 serology during the in[i]{.ul}tial years of chemotherapy \[[@pntd.0003964.ref017]\]. Subgroup B comprised 23 patients under long term benzimidazole therapy (up to 25 years), who were either inoperable (n = 15) or had either a recurrence after resection (n = 3) or an R1 resection (n = 5). They were monitored regularly by EmII/3-10 serology (every 6--12 months) and imaging. At variable time intervals after starting albendazole treatment a FDG-PET/CT was obtained.

Patients form both groups that fulfilled the inclusion criteria were included in the study and stopped treatment. After treatment stop all patients were followed prospectively with Emll/3-10 serology every 3 months. Imaging studies were performed at start and then every 12 months or at shorter intervals when AE-recurrence was suspected.

Ethics statement {#sec009}
----------------

The study was performed according to the declaration of Helsinki. The protocol was approved by the ethical committee of the canton Zurich (Kantonale Ethikkommission des Kanton Zürich), Switzerland and written informed consent was obtained from all patients (clinicaltrials.gov:[NCT00658294](https://clinicaltrials.gov/ct2/show/NCT00658294)).

Study procedures {#sec010}
----------------

The FDG-PET/CT protocol has recently been published \[[@pntd.0003964.ref021]\]. Images were analyzed by 2 board certified nuclear physicians as described previously and a semi-quantitative FDG-uptake grading scale from 0 to 4 was applied \[[@pntd.0003964.ref021]\].

ELISA using the recombinant Emll/3-10 antigen was performed as previously reported \[[@pntd.0003964.ref018],[@pntd.0003964.ref027]\]. Antibody levels \< 5 AU (arbitrary antibody units) were considered negative.

*Echinococcus multilocularis* PCR {#sec011}
---------------------------------

*Echinococcus multilocularis*-DNA was detected by PCR in fresh tissue samples obtained at surgery using primers H15 and H17 that amplify a *E*. *multilocularis* specific fragment of the mitochondrial 12S rRNA gene \[[@pntd.0003964.ref028]\].

Disease classification {#sec012}
----------------------

The disease stage was classified using the PNM system ([S1 Table](#pntd.0003964.s002){ref-type="supplementary-material"}) \[[@pntd.0003964.ref029]\].

Follow-up {#sec013}
---------

Follow-up (FU) is defined as the time from diagnosis to the last contact, the cut-off date (December 2012) or the death of the patient.

AE-recurrence was defined if new lesions were detected and/or by progression of lesions on imaging in association with a positive Emll/3-10 serology and/or a positive PET-CT. A positive PET-CT alone was not sufficient to diagnose AE-recurrence.

Statistics {#sec014}
----------

Differences between groups were analysed with Chi Square test or Fisher's exact test using SPSS software, version 20 (IBM Corporation Armonk, New York, United States). The 95% Confidence Interval (95% CI) was calculated using RStudio, Version 0.98.1062, 2009--2013 RStudio, Inc.

Results {#sec015}
=======

The baseline demographic of **group A patients** (n = 11) are summarized in [Table 1](#pntd.0003964.t001){ref-type="table"}. Nine patients had an advanced PNM stage (lllb or IV). Two patients with less advanced AE-Iesions (stage I to lIIa) were treated by long-term chemotherapy because of serious comorbidity (A1, A6).

10.1371/journal.pntd.0003964.t001

###### Typical findings of 11 newly diagnosed non-resectable AE-patients at baseline and at 2 years of initial chemotherapy.

Group A

![](pntd.0003964.t001){#pntd.0003964.t001g}

  Nr                                        Sex   Age at diagnosis   PNM at diagnosis   PET grade (0--4)   Anti-EmII/3-10 (\>5 AU)   Cessation of therapy   Comment         
  ----------------------------------------- ----- ------------------ ------------------ ------------------ ------------------------- ---------------------- --------- ----- --------------------
  A1                                        M     39                 P3N0M0             2                  2                         \+                     \+        no    HIV
  A2                                        F     52                 P4N0M0             4                  2                         \+                     \+        no    
  A4                                        F     41                 P4N0M0             4                  4                         \+                     \+        no    
  A6                                        F     72                 P1N0M0             3                  4                         \+                     neg.      no    Immuno-suppression
  A10                                       M     61                 P4N1M0             3                  4                         \+                     \+        no    
  A11                                       F     55                 P4N1M0             3                  4                         \+                     \+        no    
  A3                                        M     60                 P4N0M0             3                  0                         \+                     neg.      yes   
  A5[\*](#t001fn002){ref-type="table-fn"}   F     52                 PXN0M0             2                  0                         neg.                   neg.      yes   
  A7                                        F     62                 P4NIM0             4                  0                         \+                     neg.      yes   
  A8                                        F     60                 P4N1M0             0                  0                         neg.                   neg.      yes   
  A9                                        M     64                 P3N1M0             4                  0                         \+                     neg.      yes   

Median age (range), yrs.: 60 (39--72)

\*Recurrence after presumed radical surgery

One patient presented with a negative EmII/3-10 serology and PET-negative lesions (A8) and another one had a negative EmII/3-10 serology at baseline (A5). Nevertheless, both patients got regular chemotherapy for safety/ study protocol reasons for a minimum of 2 years.

Overall, 5 out of 11 patients of group A qualified for abrogation of chemotherapy and were included into the study (42%; 95% CI: 16.7--76,6%) (A3, A5, A7, A8, A9).

The pertinent characteristics of **group B patients** (n = 23) are summarized in [Table 2](#pntd.0003964.t002){ref-type="table"}. The 23 patients had been treated for up to 25 years by chemotherapy (median 10, range 2--25 years). AE-recurrence following \"radical\" surgery was observed in 3 patients (B1, B2, B6) and 5 additional patients had undergone R1 surgical resection many years ago (B3, B5, B13, B19, B21 ([Table 2](#pntd.0003964.t002){ref-type="table"}). Furthermore, 4 of the 23 patients had AE-recurrence following abrogation of chemotherapy in our previous study (B1, B2, B6, B16) \[[@pntd.0003964.ref012]\]. In group B, 7 out of 23 patients qualified for abrogation of chemotherapy (30%; 95% CI: 13.2--52.9%). Chemotherapy was not stopped in one of them because of metastatic breast cancer with unclear prognosis (B19).

10.1371/journal.pntd.0003964.t002

###### Typical findings of 23 patients with non-resectable AE treated by chemotherapy for up to 25 years.

Group B

![](pntd.0003964.t002){#pntd.0003964.t002g}

  Nr                                           Sex   Age at diagnosis   Treatment duration (yrs.) before FDG PET-CT   PNM      PET grade (0--4)   Anti- EmII/3-10 (\>5)   Cessation of therapy
  -------------------------------------------- ----- ------------------ --------------------------------------------- -------- ------------------ ----------------------- ----------------------
  B1[\*](#t002fn003){ref-type="table-fn"}      M     43                 22                                            P3N1M1   0                  \+                      no
  B2[\*](#t002fn003){ref-type="table-fn"}      F     33                 24                                            P3N1M0   3                  normal                  no
  B3[\*\*](#t002fn004){ref-type="table-fn"}    F     29                 21                                            P3N1M0   3                  \+                      no
  B4                                           F     63                 10                                            P3N1M0   3                  normal                  no
  B5[\*\*](#t002fn004){ref-type="table-fn"}    F     51                 8                                             P3N1M0   3                  normal                  no
  B6[\*](#t002fn003){ref-type="table-fn"}      M     34                 22                                            P4N1M0   0                  \+                      no
  B7                                           F     29                 14                                            P3N1M0   3                  normal                  no
  B8                                           F     17                 8                                             P4N0M0   3                  \+                      no
  B9                                           F     72                 16                                            P2N1M0   3                  normal                  no
  B10                                          F     59                 23                                            P3N1Mo   3                  \+                      no
  B11                                          M     44                 4                                             P3N0M0   3                  \+                      no
  B12                                          F     66                 4                                             P3N1M0   3                  \+                      no
  B19[\*\*](#t002fn004){ref-type="table-fn"}   F     44                 25                                            P3N1M0   0                  normal                  no
  B20                                          M     85                 2                                             P4N1M0   3                  normal                  no
  B21[\*\*](#t002fn004){ref-type="table-fn"}   M     48                 3                                             P4N1M0   3                  \+                      no
  B22                                          M     44                 2                                             P4N1M0   3                  normal                  no
  B23                                          M     37                 3                                             P4N1M0   3                  normal                  no
  B13[\*\*](#t002fn004){ref-type="table-fn"}   M     37                 15                                            P3N0M0   0                  normal                  yes
  B14                                          F     47                 4                                             P3N1M0   0                  normal                  yes
  B15                                          M     52                 20                                            P3N1M0   0                  normal                  yes
  B16                                          F     36                 23                                            P3N0M0   0                  normal                  yes
  B17                                          M     62                 6                                             P1N1M0   0                  normal                  yes
  B18                                          M     45                 9                                             P3N1M1   0                  normal                  yes

Median Age (range), yrs.: 44.0 (17--85)

Median duration of chemotherapy (range), yrs.: 10 (2--25)

\* Recurrence after presumed R0 surgery (RR)

\*\* R1 resection

Patients in group B were significantly younger (median age: 44 yrs. compared to 60 yrs., p\<0.001), but gender distribution and PNM-classification were similar.

The course and the final assessment of the 11 patients of groups A and B that stopped chemotherapy, representing the final study population ([Fig 1](#pntd.0003964.g001){ref-type="fig"}), are summarized in [Table 3](#pntd.0003964.t003){ref-type="table"}. The median follow-up after abrogation of chemotherapy was 70.5 (range 16--82) months. Patients who qualified for treatment abrogation were significantly older (median age 52 yrs. vs. 44 yrs.; p\<0.001), but gender distribution as well as the number of advanced stages (stage IIIb-IV) between final study population ([Table 3](#pntd.0003964.t003){ref-type="table"}) and group A and B, respectively, (Tables [1](#pntd.0003964.t001){ref-type="table"} and [2](#pntd.0003964.t002){ref-type="table"}) were similar.

![Disposition of the study population.](pntd.0003964.g001){#pntd.0003964.g001}

10.1371/journal.pntd.0003964.t003

###### Follow-up (FU) after abrogation of chemotherapy in non-resectable AE.

![](pntd.0003964.t003){#pntd.0003964.t003g}

  Nr    Sex   Age at diagnosis (yrs.)   Treatment duration (mo) before treatment abrogation   Follow-up after stopping therapy (mo)   EmII/3-10 (\>5)   Final assessment
  ----- ----- ------------------------- ----------------------------------------------------- --------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A9    M     64                        34                                                    71                                      normal            No AE recurrence
  A7    F     62                        36                                                    70                                      normal            No AE-recurrence: Short stricture of hepatic duct due sclerosing cholangitis. Successful endoscopic treatment.
  A8    F     60                        36                                                    70                                      normal            New PET pos. lesion close to AE-scar at 48 months. Surgery: necro-granulomatous lesion. AE unlikely. No chemo-therapy. Follow-up two years later: scar
  A3    M     60                        37                                                    16                                      normal            Died due to pancreatic cancer. No AE activity in resection specimen
  B14   F     47                        41                                                    60                                      normal            37 mo. After stopping chemotherapy new cystic, PET negative lesion close to AE-scar. AE recurrence unlikely. PET neg scar after two additional year of follow-up
  A5    F     52                        50                                                    68                                      normal            No AE recurrence
                                                                                                                                                        Choledocholithiasis
  B17   M     62                        78                                                    82                                      normal            No AE recurrence
  B18   M     45                        108                                                   75                                      normal            No AE recurrence
  B13   M     37                        180                                                   56                                      normal            No AE recurrence
  B15   M     52                        240                                                   78                                      normal            No AE recurrence
  B16   F     36                        276                                                   76                                      normal            No AE recurrence

Median age (range), yrs.: 52 (36--64)

Median duration of treatment (range), mo.: 50 (34--276)

Follow-up after stopping treatment (range), mo.: 70 (16--82)

The clinical course following cessation of chemotherapy was uneventful without any evidence of AE-recurrence in 6 patients. In 5 patients however, the course after cessation of chemotherapy was complicated by incidental findings ([Table 3](#pntd.0003964.t003){ref-type="table"}).

Overall, benzimidazole therapy was probably parasitocidal in at least 32% (11/34; 95% CI 17.4--50.5%) of all patients with non-resectable AE since recurrence was not observed after a median follow-up of 70.5 (range: 16--82) months following abrogation of chemotherapy (0%, 0/11; 95% CI: 0--28.5%). There was no correlation between the initial size of the FDG-PET/CT positive lesion and the chemotherapeutic efficacy (shown for patient A9 in whom therapy was parasitocidal despite an extensive initial lesion (PNM stage P3N1M0; [Fig 2](#pntd.0003964.g002){ref-type="fig"})).

![(A9): Baseline and follow-up FDG-PET/CT scans without i.v. contrast.\
a) Large and small AE-lesions (arrow) at the time of diagnosis (2003) with very strongly increased FDG uptake. b) The lesions became FDG-negative within two years of albendazole treatment. c) Progressive calcifications of AE lesions over the next 6 years after abrogation of chemotherapy (2011). No signs of FDG uptake are present.](pntd.0003964.g002){#pntd.0003964.g002}

Interestingly, anti-Emll/3-10 antibody levels were very high in 5 of 6 subgroup A patients (126.5 ± 58.6 AU) who did not fulfill the inclusion criteria and in whom no parasitocidal effect could be noted (A1-2, A4, A6, A10-11). In contrast, the 5 patients in whom a parasitocidal effect was obvious had substantially lower anti-EmII/3-10 antibody values (30.5 ± 42.9 AU) (A3, A5, A7-9)([Table 4](#pntd.0003964.t004){ref-type="table"}).

10.1371/journal.pntd.0003964.t004

###### Long-term follow-up of anti-EmII/3-10 levels in patients of group A.

![](pntd.0003964.t004){#pntd.0003964.t004g}

        Baseline   6 months   12 months   24 months   36 months   48 months   60 months   72 months   84 months   96 months
  ----- ---------- ---------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  A1    132        92         57                      12          7           0           5           11          7
  A2    172        151        133                     84                      98          109         150         
  A3    41         19         0           0           0           0           0                                   
  A4    145        128        119         128                     183         253         262         212         103
  A5    0          0          0           0           0           0           0           0           0           0
  A6    11         0          0           0                       0           0           0                       
  A7    110        75         72          0           0           0           0           0           0           0
  A8    0          0          0           0           0           0           0           0           0           0
  A9    32         0                      0           0           0           0           0           0           0
  A10   133        103        112                                 53          50          10          39          24
  A11   166        144        127         124                     160         276         265         238         

Complicated clinical courses {#sec016}
----------------------------

One patient (**A3**) underwent a Whipple operation for pancreatic cancer 4 months after abrogation of albendazole treatment. At surgery, the hepatic AE-Iesion was resected and no viable AE-tissue was histologically found. The patient died from metastatic pancreatic cancer 16 months after stopping chemotherapy. No autopsy was performed.

The second patient (**A5**) underwent a presumed radical hemihepatectomy in 1988 for AE followed by insufficient mebendazole treatment for only 3 months ([Fig 3](#pntd.0003964.g003){ref-type="fig"}). In September 2001 a severe AE-recurrence with a large lesion (7 x 12.5 cm) was detected, which was FDG-PET/CT positive and showed the typical radiological findings of AE, but anti-Emll/3-10 antibody levels remained negative. There was a rapid response to chemotherapy (Sept 2001 to Feb 2006). Albendazole was abrogated in February 2006 despite mild cholestasis that persisted since Dec 2001. In April 2008, endoscopic sphincterotomy with stone extraction was performed. The procedure was complicated by cholangitis and a perihepatic fluid collection, showing strongly increased FDG-uptake in FDG-PET/CT. Long-term antibiotic treatment was administered but no benzimidazole was given. Actually, cholestasis has regressed to almost normal values, FDG-PET/CT became negative again and anti EmII/3-10 levels remained negative all the time.

![(A5): Long-term follow-up of a large AE recurrence (Sept 2001), 3 years following presumed radical surgery).\
Albendazole was administered from Sept. 2001 until February 2006. Oligosymptomatic choledocholithiasis was treated by ERCP with papillotomy and stone extraction in April 2008. The procedure was complicated by cholangitis, which was treated by long-term antibiotic therapy. No AE-recurrence was noted during 70 months of follow-up after stopping albendazole treatment.](pntd.0003964.g003){#pntd.0003964.g003}

A third patient (**A7**) presented in 2001 with painless jaundice and a large (10 cm) necrotic AE-Iesion of the right lobe with extension to liver hilum (non-resectable). Response to albendazole treatment was excellent. FDG-PET/CT and EmII/3-10 serology became negative. Medical treatment was stopped in 2005 despite persistent mild cholestasis. Abrogation of chemotherapy was followed by marked painless jaundice. ERCP in June 2006 showed a filiform (2 cm) stricture of the common bile duct compatible with \"sclerosing-cholangitis\" as previously described \[[@pntd.0003964.ref030]\]. FDG-PET/CT and anti-Emll/3-10 levels remained negative. The biliary obstruction was successfully treated by endoscopic intervention including stenting. Since AE recurrence could not be excluded and the patient developed at approximately the same time an inoperable uterine cancer, which was treated with irradiation and cytostatic therapy, albendazole treatment was resumed and continued until the last follow-up (Oct. 2012), even though a firm proof of AE recurrence was lacking.

In the next patient (**A8**), albendazole therapy was carried out from Oct 2002 to Nov 2005 for non-resectable AE (segment V, VI, VII). After treatment abrogation (Nov 05), the clinical course over the next 3 years was uneventful. In Dec. 2008, a markedly elevated sedimentation rate (clinically unexplained) was noted which persisted also in July 2009. In Oct. 2009, a new cystic lesion adjacent to the preexistent AE-Iesion (segment VI) was detected by CT. The anti-Emll/3-10-antibody levels were negative, and the lesion showed diffusely increased FDG-uptake in PET/CT. The lesion was resected and a sterile, subacute necro-granulomatous inflammation of unknown etiology was revealed by histology. *Echinococcus multilocularis* PCR results were negative. Therefore, an AE recurrence seemed highly unlikely. Three years, later at the last follow-up (November 2012), no evidence for AE recurrence was noted.

In patient B14, a non-resectable AE-lesion of the right and caudate liver lobe with partial occlusion of the portal vein was treated with albendazole between Jul. 2003 and Dec. 2009. The treatment was well tolerated, and the patient qualified for abrogation of therapy in Dec. 2009. However, a new cystic lesion was detected by CT in segment VI, adjacent to the previous AE-lesion. A wait-and-see strategy was adopted with regular follow-up but without resumption of chemotherapy. Follow-up was uneventful, and a CT scan showed a calcified scar, but no evidence of AE-recurrence in Nov. 2012.

Discussion {#sec017}
==========

Our prospective long-term study provides strong evidence that chemotherapy was parasitocidal in at least 11 out of 34 patients (32%) with non-resectable AE. These results contradict the current opinion of an exclusively parasitostatic effect with the need for lifelong medical therapy \[[@pntd.0003964.ref002]--[@pntd.0003964.ref004],[@pntd.0003964.ref007],[@pntd.0003964.ref009],[@pntd.0003964.ref014]\]. Moreover, patient follow-ups by FDG-PET/CT and Emll/3-10 serology represent a strategy to assess parasite viability and to decide whether treatment can be safely discontinued.

Our data seem to be in discordance with a clinical study including 23 patients with non-resectable AE in Ulm (Germany) \[[@pntd.0003964.ref014]\]. Based on negative FDG-PET-scans, benzimidazole therapy of variable duration was stopped in 15 patients, but evidence of AE-recurrence was noted in 53% within the following 18 months. These data suggested a poor correlation between FDG-PET-scan results and larval viability \[[@pntd.0003964.ref014]\].

In contrast to our study (33% negative FDG-PET/CT), the rate of FDG-PET negative lesions after long-term chemotherapy was surprisingly high (65%) in the Ulm study.

In previous studies, the interval between abrogation of chemotherapy and AE recurrence averaged 33.6 (range 12--156) months \[[@pntd.0003964.ref012],[@pntd.0003964.ref018]\] and less than 18 months \[[@pntd.0003964.ref014]\]. No AE-recurrence was noted on an average 29.2 (range 6.8--66) and 23 (range 8--37) months, respectively, after cessation of chemotherapy in two recent series from the same group (n = 5 and n = 7) \[[@pntd.0003964.ref031],[@pntd.0003964.ref032]\].

In the present series, the patients were followed for a median of 70 (range 16--82) months after abrogation of chemotherapy. Accordingly, the risk of missing AE-recurrence after stopping chemotherapy in our series appears small, although AE-recurrence has been reported in single cases after 106 \[[@pntd.0003964.ref033]\] and 156 months \[[@pntd.0003964.ref008]\] respectively.

The problem of diagnosing AE-recurrence following abrogation of chemotherapy is illustrated by the numerous incidental findings in our series (A3, A5, A7, A8, B14). In particular, cholestasis after chemotherapy abrogation was probably not caused by AE-recurrence (A5, A7), since follow-up data were compatible with a sclerosing-cholangitis like syndrome, a largely unknown syndrome \[[@pntd.0003964.ref030]\] in one and oligosymptomatic (incidental) choledocholithiasis in the second patient.

Two patients of our series developed new liver lesions (A8, B14). Causes are unexplained, but AE-recurrence seemed very unlikely particularly because levels of specific antibodies (including anti-Emll/3-10 antibodies) remained unchanged and no lesion progression was observed during a three year follow-up period without chemotherapy.

According to the current literature, the predictive value of post-chemotherapy immunsurveillance is limited \[[@pntd.0003964.ref002],[@pntd.0003964.ref004],[@pntd.0003964.ref009],[@pntd.0003964.ref034],[@pntd.0003964.ref035]\]. In contrast, our data indicate that anti-EmII/3-10 levels are valuable for assessing parasite viability (\[[@pntd.0003964.ref018]\], present series). In our experience, the anti-Emll/3-10 levels are more sensitive markers for larval viability than the serological results obtained by the Em2-plus test containing two antigens (Em2 and EmII/3-10) \[[@pntd.0003964.ref036]\] used by Reuter et al. \[[@pntd.0003964.ref014]\].

Surprisingly, we found that baseline anti-Emll/3-10 levels appear to have a predictive value with regard to a parasitocidal efficacy of albendazole treatment. These levels were very high (\>120 AU units) in 5 of 6 patients of group A in whom no parasitocidal effect was observed, in contrast to the 5 patients with low levels (\< 120 AU) in whom there was a probable parasitocidal effect ([Fig 3](#pntd.0003964.g003){ref-type="fig"}). The predictive value of baseline anti-EmII/3-10 serology for parasitocidal vs. parasitostatic efficacy deserves further studies in larger series of AE patients.

It is largely unknown which factor(s) are important for the parasitocidal effect of benzimidazole treatment. It has been suggested that a parasitocidal effect may be related to the duration of therapy \[[@pntd.0003964.ref011],[@pntd.0003964.ref015]\]. This assumption was not confirmed in recent studies \[[@pntd.0003964.ref014]\] and the present series. In particular, no parasitocidal efficacy was noted in the majority of 23 patients (group B) despite chemotherapy for up to 25 years ([Table 2](#pntd.0003964.t002){ref-type="table"}).

The parasite host-immune-interaction probably plays an important role for the outcome of AE-infection \[[@pntd.0003964.ref037]\]. First, AE-lesions may be inactivated spontaneously i.e. "died-out" AE \[[@pntd.0003964.ref002],[@pntd.0003964.ref004],[@pntd.0003964.ref037],[@pntd.0003964.ref038]\]. Second, the impact of immune deficiency as (co)-factor for lacking parasitocidal efficacy is supported by 2 patients in group A, i.e. HIV-infection (A1) or continuous immunosuppressive therapy (rheumatoid arthritis; A6). According to a recent French series, a family clustering of AE was noted in 20 of 153 patients (13%) \[[@pntd.0003964.ref039]\]. Such an association was not observed in our series. Third, AE progression in AIDS \[[@pntd.0003964.ref040]\] or in immune-compromised patients following liver transplantation \[[@pntd.0003964.ref041]\] as well as in animal experiments with cyclosporine-induced immunodeficiency \[[@pntd.0003964.ref042]\] emphasize the impact of an intact immune system on the evolution of AE disease.

In conclusion, according to our knowledge, this is the largest prospective study documenting a parasitocidal efficacy of long-term benzimidazole chemotherapy in 11 patients with AE. Negative anti-EmII/3-10 levels combined with normalized FDG-PET scan were reliable parameters to predict a recurrence-free survival after stopping benzimidazole treatment. Until our data are confirmed long-term benzimidazole treatment is still the standard of care for patients with unresectable AE, after R1 resection or after liver transplantation \[[@pntd.0003964.ref002]\]. To stop long-term benzimidazole treatment should only be considered in experienced center using the same approach as outlined in this manuscript. Especially positive PET-CT findings should be carefully evaluated and the diagnosis of recurrence should not be based on an isolated positive PET/CT finding alone. In addition it is mandatory that patients are closely followed and therefore stopping long-term benzimidazole treatment should only be considered in patients who will be compliant with follow-up examinations. In our previous study we could show that especially monitoring with the EmII/3-10 serology is very useful to predict recurrence \[[@pntd.0003964.ref018]\]. Finally as patients safety is crucial, restarting benzimidazole treatment should also be considered in patients requiring any kind of immunosuppressive treatment such as chemotherapy.
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